Fuji Pharma (4554) · InitiativeAchieved
Demolition of the Injectable Drug Manufacturing Building at the Toyama Plant in Connection with Production Site Restructuring
First written in FY2019. 1 of 2 entries say "Achieved", first in FY2020. Latest entry: FY2020.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Additional Costs Associated with Plant Closure and Business Structure ImprovementA theme 19 companies write about · 20 as a headwind · 1 as a tailwind
The whole theme swung hardest in 2024: 4 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.Full recordFilings, disclosures and news, newest first
- FY2020AchievedAnnual report
「Construction of an injectable drug plant, now the second formulation building, on the Toyama Plant site; derecognized in September 2020」
The Company has recorded in its corporate history that the injectable formulation building at the Toyama Plant, whose demolition was decided in the previous fiscal year, was derecognized in September 2020. - FY2019First statedAnnual report
「As a result, in the current consolidated fiscal year, we recognized the full carrying amount as an impairment loss following the decision to demolish the injectable formulation building at the Toyama Plant as part of the reorganization of production facilities.」
The Company has disclosed for the first time its decision to demolish the injectable formulation building at the Toyama Plant as a specific measure in the reorganization of production facilities.